Equities

PAVmed Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
PAVM:NAQ

PAVmed Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)9.95
  • Today's Change-0.11 / -1.09%
  • Shares traded36.02k
  • 1 Year change-52.00%
  • Beta0.8789
Data delayed at least 15 minutes, as of Mar 03 2026 19:40 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.

  • Revenue in USD (TTM)29.00k
  • Net income in USD-595.00k
  • Incorporated2014
  • Employees39.00
  • Location
    PAVmed Inc360 Madison Avenue, 25Th FloorNEW YORK 10017United StatesUSA
  • Phone+1 (212) 949-4319
  • Fax+1 (302) 655-5049
  • Websitehttps://pavmed.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Beyond Air Inc6.92m-31.00m9.38m61.00--0.9229--1.35-5.43-5.431.130.96510.19533.287.74113,508.20-90.33-81.28-107.51-103.401.82---462.58-4,167.724.77-13.320.7262--219.6721.6622.60--166.66--
REMSleep Holdings Inc12.27k-3.01m9.38m6.00--38.90--764.66-0.0019-0.00190.000010.00020.01930.8251.51---472.04-107.16-671.87-177.2194.87---24,509.54-1,456.221.73--0.2146---42.47--39.36--5.18--
SeaStar Medical Holding Corp881.00k-13.67m9.77m19.00--0.806--11.09-16.43-16.430.68743.360.0876--6.1046,368.42-135.86---290.37--95.35---1,551.08--3.64--0.00------5.34------
QHSLab Inc2.61m-386.75k9.90m4.00------3.79-0.0373-0.03730.1997-0.05421.4926.3812.80653,480.00-22.10-39.97---284.7966.3755.22-14.80-44.620.17140.30381.63--51.31--44.65------
SINTX Technologies Inc1.27m-16.56m10.86m20.00--2.51--8.55-6.93-6.930.58941.130.11211.345.5263,500.00-86.86-51.41-121.23-64.3452.0566.36-775.12-575.951.60-302.730.0143--9.9033.18-33.06--36.24--
BioRegenx Inc1.93m-18.93m11.54m5.00------5.98-0.0195-0.01950.002-0.00380.20833.1547.03385,874.00-204.29---341.72--78.14---980.96--0.0416-8.01-----31.40---540.38------
BioNano Genomics Inc28.72m-38.59m11.60m98.00--0.2228--0.4039-737.92-737.929.995.120.34511.455.84293,061.20-46.37-58.31-69.84-72.5345.9718.60-134.36-487.421.82--0.07---14.7924.8951.82--11.02--
Modular Medical Inc0.00-26.78m12.20m54.00--2.07-----0.4926-0.49260.000.07570.00----0.00-239.01-171.42-284.19-207.14------------0.00-------7.75--57.07--
Trinity Biotech PLC (ADR)49.41m-35.91m12.91m401.00------0.2613-2.19-2.223.19-2.570.50941.523.48123,217.00-37.02-23.08-52.54-35.9733.8138.51-72.67-32.840.4083-1.731.79--8.31-7.4115.33---3.22--
Vivos Therapeutics Inc17.32m-17.10m13.31m109.00--4.60--0.7685-1.88-1.881.930.30630.8449--13.38158,871.60-83.45-85.27-120.33-138.5155.7467.27-98.77-108.16----0.7785--8.915.7018.02--26.46--
Vicarious Surgical Inc0.00-53.59m13.67m123.00--0.8122-----9.04-9.040.002.360.00----0.00-97.47-35.33-109.17-37.33------------0.00------11.04---6.06--
PAVmed Inc29.00k-595.00k14.37m39.000.90610.9144--495.69-20.47-20.470.015546.570.0009--3.05743.594.17-115.648.14-8,726.29-520.69--4,931.04-3,891.34----0.2111--22.15--148.24--15.12--
Movano Inc500.00k-17.05m14.79m32.00------29.58-6.54-6.540.0883-2.040.04850.82163.5115,625.00-165.32-159.40-360.23-208.33-270.20---3,409.60-11,662.690.3451-12.462.32------18.97---9.25--
United Health Products Inc0.00-2.95m17.85m10.00---------0.0116-0.01160.00-0.01290.00----0.00-2,405.94-4,956.01-----------137,625.90---16.29--------23.69------
Data as of Mar 03 2026. Currency figures normalised to PAVmed Inc's reporting currency: US Dollar USD

Institutional shareholders

5.71%Per cent of shares held by top holders
HolderShares% Held
First Manhattan Co. LLCas of 31 Dec 202523.80k2.24%
UBS Securities LLCas of 31 Dec 20257.33k0.69%
The Vanguard Group, Inc.as of 31 Dec 20255.92k0.56%
Geode Capital Management LLCas of 31 Dec 20255.63k0.53%
Vanguard Fiduciary Trust Co.as of 31 Dec 20255.43k0.51%
Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 20253.58k0.34%
BlackRock Fund Advisorsas of 31 Dec 20252.41k0.23%
G1 Execution Services LLCas of 31 Dec 20252.27k0.21%
GSA Capital Partners LLPas of 31 Dec 20252.20k0.21%
CapFinancial Partners LLCas of 31 Dec 20252.17k0.20%
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.